Literature DB >> 29277667

Triclosan and its derivatives as antimycobacterial active agents.

Rudolf Vosátka1, Martin Krátký1, Jarmila Vinšová2.   

Abstract

Tuberculosis (TB) represents one of the leading causes of morbidity and mortality worldwide. Development of new potential drugs is essential because of the existence of latent TB and expansion of drug-resistant TB forms (multidrug-resistant and extensively drug-resistant tuberculosis). Triclosan is a widely used broad-spectrum biocidal agent. It has been shown to inhibit InhA, an essential enoyl acyl carrier protein reductase, resulting in the lysis of Mycobacterium tuberculosis. Triclosan can be considered as a promising compound for the inhibition of InhA and suppression of mycobacterial growth, because this polychlorinated molecule doesn't require any activation and it is able to affect the function of InhA directly. This approach enables to circumvent resistance to isoniazid. The aim of this review is to describe current knowledge about triclosan and its analogues as potential antimycobacterial agents.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antitubercular activity; Diphenyl ether; Enzyme inhibition; InhA; Structure-activity relationship; Triclosan

Mesh:

Substances:

Year:  2017        PMID: 29277667     DOI: 10.1016/j.ejps.2017.12.013

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  7 in total

Review 1.  Recent Progress in the Development of Novel Mycobacterium Cell Wall Inhibitor to Combat Drug-Resistant Tuberculosis.

Authors:  Tafere Mulaw Belete
Journal:  Microbiol Insights       Date:  2022-05-23

2.  Evaluation of Triclosan Effects on Cultured Swine Luteal Cells.

Authors:  Giuseppina Basini; Simona Bussolati; Simone Bertini; Fausto Quintavalla; Francesca Grasselli
Journal:  Animals (Basel)       Date:  2021-02-25       Impact factor: 2.752

3.  New InhA Inhibitors Based on Expanded Triclosan and Di-Triclosan Analogues to Develop a New Treatment for Tuberculosis.

Authors:  Sarentha Chetty; Tom Armstrong; Shalu Sharma Kharkwal; William C Drewe; Cristina I De Matteis; Dimitrios Evangelopoulos; Sanjib Bhakta; Neil R Thomas
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-14

Review 4.  Advances in Key Drug Target Identification and New Drug Development for Tuberculosis.

Authors:  Jie Mi; Wenping Gong; Xueqiong Wu
Journal:  Biomed Res Int       Date:  2022-02-25       Impact factor: 3.411

Review 5.  Triclosan: A Small Molecule with Controversial Roles.

Authors:  Maria Stefania Sinicropi; Domenico Iacopetta; Jessica Ceramella; Alessia Catalano; Annaluisa Mariconda; Michele Pellegrino; Carmela Saturnino; Pasquale Longo; Stefano Aquaro
Journal:  Antibiotics (Basel)       Date:  2022-05-30

6.  Identification of Novel Inhibitor of Enoyl-Acyl Carrier Protein Reductase (InhA) Enzyme in Mycobacterium tuberculosis from Plant-Derived Metabolites: An In Silico Study.

Authors:  Kratika Singh; Niharika Pandey; Firoz Ahmad; Tarun Kumar Upadhyay; Mohammad Hayatul Islam; Nawaf Alshammari; Mohd Saeed; Lamya Ahmed Al-Keridis; Rolee Sharma
Journal:  Antibiotics (Basel)       Date:  2022-08-01

7.  Design and Synthesis of Highly Active Antimycobacterial Mutual Esters of 2-(2-Isonicotinoylhydrazineylidene)propanoic Acid.

Authors:  Václav Pflégr; Jana Maixnerová; Jiřina Stolaříková; Adrián Pál; Jana Korduláková; František Trejtnar; Jarmila Vinšová; Martin Krátký
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.